The role of JAK/STAT signaling pathway and its inhibitors in diseases.

By Ping Xin, Xiaoyun Xu, Chengjie Deng, Shuang Liu, Youzhi Wang, Xuegang Zhou, Hongxing Ma, Donghua Wei, Shiqin Sun. International Immunopharmacology, 2020

849 citations recorded by the source corpus.

The JAK/STAT signaling pathway is an universally expressed intracellular signal transduction pathway and involved in many crucial biological processes, including cell proliferation, differentiation, apoptosis, and immune regulation. It provides a direct mechanism for extracellular factors-regulated gene expression. Current researches on this pathway have been focusing on the inflammatory and neoplastic diseases and related drug. The mechanism of JAK/STAT signaling is relatively simple. However, the biological consequences of the pathway are complicated due to its crosstalk with other signaling pathways. In addition, there is increasing evidence indicates that the persistent activation of JAK/STAT signaling pathway is closely related to many immune and inflammatory diseases, yet the specific mechanism remains unclear. Therefore, it is necessary to study the detailed mechanisms of JAK/STAT signaling in disease formation to provide critical reference for clinical treatments of the diseases. In this review, we focus on the structure of JAKs and STATs, the JAK/STAT signaling pathway and its negative regulators, the associated diseases, and the JAK inhibitors for the clinical therapy.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d83f6e4afcf1f6c02e1ad45b44851d48e30e9dc3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Xia Zhao
2. Maorong Fu
3. Jing Li
4. S. Savvides
5. Wei Wang
6. I. Marković
7. Xiaoying Hu

Citations in the corpus

• The JAK/STAT signaling pathway: from bench to clinic (2021, background): “Currently, many JAK inhibitors have achieved efficacy in many clinical settings, and more medications are currently being studied.(10) In this review, we aim to provide updated and comprehensive views of the JAK/STAT signaling pathway at the cellular, molecular, and genomic levels, and elucidate the”
• Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer (2020, background): “Such modulators would be expected to have distinct modes of action compared to already available inhibitors known to target intracellular portions of cytokine receptors or specific intracellular signaling components downstream of cytokine-dependent receptor activation (116, 117).”